Detailed Narrative
Strategic Separation Update
Corteva announced its intent to separate into two public companies, Seed and Crop Protection, by the second half of 2026. This proactive decision aims to better position each business for maximum long-term growth by allowing them to pursue distinct opportunities. The seed genetics landscape is evolving with new technologies like gene editing and AI, while crop protection is shifting towards multiple modes of action and biological solutions. The separation process is on schedule, with a global CEO search initiated for Corteva, and the company is committed to delivering strong results throughout the transition.
Strong Operational Execution and Cost Control
The company continues to execute well operationally, achieving double-digit operating EBITDA gains in both Seed and Crop Protection businesses. Corteva now expects to deliver over $600 million in controllable benefits this year, an improvement from the prior estimate of $530 million. Year-to-date, the company has realized over $500 million in productivity and cost benefits, including lower seed commodity costs, raw material deflation, and productivity actions. This focus on controllables has been a key driver of margin expansion.
Crop Protection Innovation and Market Dynamics
The Crop Protection business is delivering solid earnings and margin growth, driven by demand for differentiated technology. The company announced a new brand name, Varpelgo, for its next-gen insecticide active, expected to launch in the early 2030s and reach over $750 million in peak revenues. The $9 billion Crop Protection Technology pipeline includes billion-dollar product families and biologicals. While competitive pricing persists in some major markets, underlying farmer demand for applications remains on track, and the company anticipates low single-digit growth for the overall crop protection industry in 2026.
Latin America Market Conditions and Risk Management
Credit market conditions in Latin America, particularly Brazil and Argentina, are experiencing higher borrowing costs and increased bankruptcies. However, Corteva is managing this risk effectively, with minimal losses and improved past dues as a percentage of accounts receivable. The company's go-to-market strategy and robust barter system, which accounts for approximately 40% of total sales in Brazil, are key differentiating factors in mitigating exposure in the region.
Biologicals Growth and Future Potential
Corteva's biologicals business has shown strong growth, increasing from approximately $400 million to nearly $600 million in revenue since entering the market. The company is pleased with the progress of moving these products globally, including a successful branded launch in North America. Management expects continued strong high single-digit to low double-digit growth rates for biologicals in the foreseeable future, viewing it as an area for potential M&A or collaboration to further expand the portfolio.
Gene Editing and Hybrid Wheat Development
The company views gene editing as a very exciting and powerful technology for the future of agriculture, transforming farming practices. While gene editing capabilities may become widely available, differentiation will come from access to high-quality germplasm and robust supply chain production. Corteva is also excited about its hybrid wheat technology, which is in its third year of plant trials and on track for a 2027 launch, with consistent 10% to 15% yield improvements and a projected $1 billion revenue opportunity in the next decade.